NCT07249905 2026-03-03
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
Clinical Trials
12 trialsNCT07443137 2026-03-02
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Stanford University
Phase 1 Not yet recruiting
NCT06014762 2026-02-27
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics, Inc.
Phase 1 Recruiting
NCT03316573 2026-02-10
Pembrolizumab in Neoplasms or Lymphomas
Dana-Farber Cancer Institute
Phase 2 Suspended
NCT07121946 2026-02-10
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics, Inc.
Phase 1 Recruiting
NCT07389356 2026-02-05
Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase NA Not yet recruiting
NCT05563844 2026-02-04
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2 Active not recruiting
NCT03740529 2026-01-27
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Phase 1/2 Completed
NCT06846463 2026-01-23
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Virginia Commonwealth University
Phase 2 Recruiting
NCT07288879 2026-01-08
DALY II Japan
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT03674411 2026-01-06
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
Phase 2 Active not recruiting
NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting